Skip to main content
letter
. 2020 Jun;105(6):e272–e275. doi: 10.3324/haematol.2019.231407

Figure 1.

Figure 1.

CONSORT diagram of the NOHARM trial. A total of 199 young children with sickle cell anemia (SCA) completed Year 1, either fixed-dose hydroxyurea or placebo treatment. All but one then entered the open-label treatment phase and 192 completed the study after Year 2 of hydroxyurea treatment. There were five deaths in the open-label treatment phase; including two (*) that occurred within the scheduled 30-day window after the final end-of-study visit.